Family is coming first for Kevin O’Boyle.
O'Boyle to Leave NuVasive
2 min read Premium comments
O’Boyle, who has been NuVasive’s financial chief as the company grew from a small spine company to a publicly traded powerhouse over the last six years, is planning on leaving NuVasive by the end of the year.
The company announced on September 2 that O’Boyle was resigning from his positions of Executive Vice President and Chief Financial Officer so that, “he is able to attend to personal and family obligations.”
“I have thoroughly enjoyed serving as part of the management team of NuVasive, helping to build the company into a major player in the spine industry with a unique culture of Absolute Responsiveness, ” O’Boyle said in a prepared statement. “Unfortunately, personal obligations make a long-term position as CFO of NuVasive extremely difficult to maintain. I would like to thank all NuVasive shareowners for making my time at NuVasive a remarkable one.”
Said Alex Lukianov, NuVasive’s Chairman and Chief Executive Officer:
Kevin has been part of our executive team for the past six years, from fundraising as a private company, to our initial public offering, to helping build our corporate infrastructure for long-term growth and continued market share gains. We thank him for his contributions to the company and wish him well as he attends to important family and personal matters.
Replacement Sought
NuVasive is searching for a new Chief Financial Officer and O’Boyle said that he would potentially remain past December 31 to assist in the recruitment of his replacement and to effect an orderly transition.
O’Boyle became NuVasive’s CFO in 2003 and Executive Vice President in 2004.
Prior to joining NuVasive, he held various positions, including Chief Financial Officer, with ChromaVision Medical Systems, Inc., a firm specializing in the oncology market. He also spent seven years with Albert Fisher North America, Inc., a food company. He received a B.S. in Accounting from the Rochester Institute of Technology and successfully completed the Executive Management Program at the University of California at Los Angeles, John E. Anderson Graduate Business School.
Calming the investor community, Lukianov noted that the company’s financial and business condition, “is vibrant and healthy as we continue to expand our presence in the market. We have begun the comprehensive search process to identify a new CFO and will be conducting a thorough review to identify the best possible leader to help take us to $1 billion in sales and beyond…”
O’Boyle helped lead NuVasive to an expected $365 million in sales for the current year.
All the Best Mr. O’Boyle
No further information was provided about O’Boyle’s personal and family obligations, but we wish one of the good guys of spine all the best.
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.